Compare DLTR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTR | ILMN |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 20.4B |
| IPO Year | 1996 | 2000 |
| Metric | DLTR | ILMN |
|---|---|---|
| Price | $129.44 | $122.13 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 18 | 17 |
| Target Price | $122.88 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 2.7M | 2.2M |
| Earning Date | 03-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 3.72 | ★ 5.45 |
| Revenue | ★ $17,578,500,000.00 | $4,343,000,000.00 |
| Revenue This Year | $12.95 | $6.56 |
| Revenue Next Year | $6.27 | $5.49 |
| P/E Ratio | $34.33 | ★ $22.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.80 | $68.70 |
| 52 Week High | $142.40 | $155.53 |
| Indicator | DLTR | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 40.90 |
| Support Level | $113.11 | $114.88 |
| Resistance Level | $132.48 | $126.00 |
| Average True Range (ATR) | 4.29 | 4.00 |
| MACD | 0.34 | 0.39 |
| Stochastic Oscillator | 42.64 | 57.29 |
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2024, Dollar Tree generated over $17 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.